# Sarepta Therapeutics (SRPT) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/SRPT
## Company Profile
- Ticker: SRPT
- Exchange: NASDAQ
- Sector: Gene Therapy
- Location: United States
- Tags: Gene Therapy
## Stock Data
- Close: 15.93 USD
- Market cap: 1715613607.5 USD
- Last updated: 2026-08-05
## Business Overview
### Precision Genetic Medicine
Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy.
### ELEVIDYS
ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients aged four years and older with confirmed Duchenne mutations.
### Exon-Skipping Franchise
EXONDYS 51, VYONDYS 53 and AMONDYS 45 use phosphorodiamidate morpholino oligomers to skip specific dystrophin exons in genetically eligible Duchenne patients.
### siRNA Platform
SRP-1001 and SRP-1003 are integrin-targeted siRNA candidates in Phase 1/2 development for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.
### Global Commercial Partnerships
Sarepta commercializes directly in the United States and works with Roche and Chugai on ELEVIDYS outside the U.S., combining internal development with regional partnerships.
## Why The Stock Is Moving

The latest monitored company update is “Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Sarepta’s key catalyst window is still Elevidys, including regulatory / safety scrutiny, plus any DMD pipeline update that can stabilize the story. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.

## Recent News
- 2026-08-05 20:05 EST — [Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-second-quarter-2026-financial-results-and-recent--2e896069) — Source: Sarepta Therapeutics
- 2026-07-29 21:00 EST — [Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635--bf21b718) — Source: Sarepta Therapeutics
- 2026-07-27 12:30 EST — [Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-appoints-michael-severino-m-d-chief-executive-officer-5e7c3ca8) — Source: Sarepta Therapeutics
- 2026-07-22 12:30 EST — [Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-announce-second-quarter-2026-financial-results-f4a4e3da) — Source: Sarepta Therapeutics
- 2026-06-30 12:30 EST — [Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®](https://biopharmsignal.com/news/SRPT/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-40aea7f9) — Source: Sarepta Therapeutics